TrialAdvances in therapy2025

First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study.

Shukui Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.